NSCs-derived extracellular vesicles exhibit neuroprotective effect in Parkinson’s disease models

Parkinson’s disease (PD) is a devastating neurodegenerative disorder that progressively impairs movement and cognitive function due to the loss of dopamine-producing neurons in the brain. While current treatments help manage symptoms, they do not stop or slow the disease’s progression. One of the biggest challenges in developing effective therapies is the blood-brain barrier (BBB), a protective filter that prevents many drugs from reaching the brain.

Researchers from IBR-CONICET, have explored a promising new approach—using extracellular vesicles (EVs) derived from neural stem cells (NSC-EVs) to protect and support vulnerable neurons. EVs are tiny particles naturally released by cells, and they play a critical role in communication between neurons. Importantly, they can cross the BBB, making them a potential vehicle for delivering therapeutic molecules directly to the brain.

In this study, NSC-EVs were tested in laboratory models of PD. The results showed that these vesicles significantly improved the survival of dopamine-producing neurons by reducing apoptosis (cell death) and enhancing their resistance to damage. The researchers also discovered that NSC-EVs are naturally enriched with Catalase, a powerful antioxidant enzyme that helps reduce oxidative stress—one of the main contributors to neuron degeneration in PD.

NSC-EVs purification and characterization

(a) Schematic representation of EVs purification protocol. (b) Size distribution by Dynamic Light Scattering. (c) Concentration and size distribution by Nanoparticle Tracking Analyzer (NTA) (d) Representative image of the morphological analysis done by transmission electron microscopy (TEM) (e) Representative Western blot of exosome protein marker. The figure displayed here are cropped from the same gels/blot, and without high-contrast (overexposure).

By leveraging the neuroprotective properties of NSC-EVs, this study highlights a promising avenue for developing treatments that not only alleviate symptoms but also protect and preserve brain cells. While more research is needed to bring this therapy to clinical trials, these findings represent a significant step toward creating innovative, disease-modifying treatments for Parkinson’s disease.